Vendégkönyv Debreceni Mű-terem Galéria

Συγγραφείς: Debreceni Művelődési Központ/ ismeretlen

Συνεισφορές: Lóska Lajos, Breznay Pál, Sóváradi Valéria, Székelyi Kati, Szentei Tamás, Dr. Tar Károlyné, Sol Oriens Kórus, Gaál Ágnes, Fritz Béla, Monika Fritz, Molnár Judit, Somogyi Béla, Halász János, Somogyi Béla, Bíró Rozália, Sulyok Géza, Csonka László, Kiss István, Csorján Melitta, Oana-Ekaterina Baruta, Szentei Tamás, Dr. Varga Gyula, Kodály Zoltán Zeneművészeti Szakközépiskola és AMI növendékei fuvolán, Földi László, Máthé András, Szitás Tamás, Gyöngy Enikő, Kozmáné Bődi Ildikó, Szántai Lajos, Kenyeres Ilona, Bárdosi Ildikó, Lestyán Goda János, Beleznai Péter, Wehner Tibor, Barra Ákos, Sulyok Géza,Juhász Erika, Tóth Gábor, Éles Gergő, Bányász Judit, Bein Klára,Nyári Ildikó, Dr. Feledy Balázs, Somogyi Béla, Potyók Tamás, Kodály Zoltán Zeneművészeti Szakközépiskola és Alapfokú Művészetoktatási Intézmény növendékei, Nánai Zsuzsanna,Baruta Oana Ecaterina, Csorján Melitta Catalina Mos, Mallár Gabriella,, Vágfalvi Ottó, Somogyi Béla, Cserép László, László János, Papp András, Debreceni Zeneművészeti Kar hallgatói, Kujbus János, Tóth Miklós, Zakar Zoltán Gajdos Márk, Kocsis István Tamás, Bölcskei Gusztáv,Hapák József, Virginás István, Wrábel Erzsébet, Székelyhidi Ágoston, Kocsis Ágnes, Somogyi Béla, Szutorisz-Szügyi Csongor, Verebes György, Papp László, Szabó Antónia, Pap Gábor, Pál Eszter, Makoldi Sándor, Szabó Károly, Süli-Zakar Szabolcs, Halász János, Bíró Rozália, Tarnóczi József, Dórka és barátai, Tolvaj Panna, Tarasie Daniel Iosif, Csiszer Attila, Ludman Éva, Márton Enikő, Kistof Huf, Paul Huf, Dr. Anne Hacket, Thomas Glatz, Sulyok Géza, Balázs Klára, Göbölyös Márta, Manninger Mária, Dr. Feledy Balázs, Kodály Zoltán Zeneművészeti Szakközépiskola, Alapfokú Művészetoktatási Intézmény és Kollégium növendékei, Dr. Seres Géza, Fátyol Zoltán, Guessous Majda Mária, Éles Gergő Péter, Tóth Gábor, Kalmárné Horóczi Margit, Dr. Vitéz Ferenc, Rozmaring Nyugdíjas Népdalkör, Somogyi Győző, Kodály Zoltán Zeneművészeti Szakközépiskola, Alapfokú Művészetoktatási Intézmény és Kollégium növendékei, Tóth Miklós, Orosz Csaba, Kujbus János, Kovács Tibor, Földi Péter, Makoldi Sándor, Bíró Imre, Magyari Ágnes és tanítványai-Ludnai Mátyás és Tóth Huba, Péreli Zsuzsa, Erdei Lilla, Tolcsvay László, Szabó Henrietta, Juha Richárd, Dr.Vitéz Ferenc, Süli István, Varga Tamás, Kanyó Ferenc, Papp László, Szentei Tamás, Potyók Tamás, Jéger Dorka, Jéger Attila, Jéger Zsombor, Bakó Ilona, Bakonyvári M. Ágnes, Varga József, Dr.Éles Csaba,Tálas Csilla, Dr. Márkus Béla, Bárdosi Ildikó, Molnár Miklós, Mészáros Éva, F. Dr. Dózsa Katalin, Tóth Eleonóra, Ludman Éva, Aknai Katalin, Csonka László, Tóth József, Cs. Uhrin Tibor, Győri László, Makoldi Sándor, Oláh Tibor, Pikó Sándor, Sulyok Géza, Tikász Sándor, Pap Gábor, Lux együttes, Szeredás együttes

Πηγή: Debreceni Művelődési Központ
Debrecen

Διαθεσιμότητα: http://data.europeana.eu/aggregation/europeana/2048128/39264

SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

Συγγραφείς: Garrido-Castro, A.C. ^{1, 2, 3}, Kim, S.E. ⁴, Li, T. ⁴, Desrosiers, J. ^{1, 2}, Nanda, R. ⁵, Abdou, Y. ⁶, Clark, A.S. ⁷, Sacks, R.L. ⁸, O’Connor, T. ^{1, 2, 3}, Sinclair, N. ^{1, 2, 3}, Lo, S. ⁹, Augdahl, G. ^{1, 2}, Wrabel, E. ^{1, 2}, DiLullo, M. ^{1, 2}, Rahman, T. ^{1, 2}, Patel, A. ^{1, 2}, Hughes, M.E. ^{1, 2, †}, Baginska, J. ^{1, 2}, Lange, P.B. ^{1, 2}, O’Meara, T. ^{1, 2, 3}, Keenan, T.E. ^{1, 2, ‡, ¶}, Gorthi, A. ¹⁰, D’Ippolito, A. ¹⁰, Painter, C.A. ¹⁰, Eaton, M. ¹⁰, Barrett, J.C. ¹⁰, Koca, B. ^{1, 2}, Kurnia, P.T. ^{1, 2}, Perry, A.N. ^{1, 2}, Gomez Tejeda Zanudo, J. ^{1, 2}, He, M. ¹¹, Dillon, D.A. ^{2, 3, 12}, Lin, N.U. ^{1, 2, 3}, Burstein, H.J. ^{1, 2, 3}, Mittendorf, E.A. ^{2, 3, 13, §}, Jeselsohn, R. ^{1, 2, 3}, Rimm, D.L. ¹¹, Tayob, N. ^{3, 4}, Tolaney, S.M. ^{1, 2, 3, ∗}

Πηγή: In Annals of Oncology October 2026 37(10):1396-1413

Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer

Συγγραφείς: Grinshpun, A. ^{1, 2, 3}, Ren, S. ⁴, Graham, N. ⁴, DeMeo, M.K. ^{1, 2}, Wrabel, E. ^{1, 2}, Carter, J. ^{1, 2}, Tayob, N. ^{3, 4}, Pereslete, A. ^{1, 2}, Hamilton, E. ^{5, 6}, Juric, D. ^{3, 7}, Mayer, E.L. ^{1, 2, 3}, Tolaney, S.M. ^{1, 2, 3}, Krop, I.E. ^{1, 2, 3, †}, Metzger, O. ^{1, 2, 3, ∗}

Πηγή: In ESMO Open June 2024 9(6)

246P Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial

Συγγραφείς: Weiss, A.C., Jin, Q., Tayob, N., Wrabel, E., DeMeo, M., Carter, J., Fenton, M.A.A., Constantine, M., Block, C., Faggen, M., Lo, K.M.S., Openshaw, T., Yardley, D., Kennedy, L.C., Bedrosian, I., Mittendorf, E., Metzger, O., King, T.A., Hachem, H.

Συνεισφορές: Breast Cancer Alliance, Pfizer

Πηγή: Annals of Oncology ; volume 35, page S318 ; ISSN 0923-7534

Διαθεσιμότητα: http://dx.doi.org/10.1016/j.annonc.2024.08.189
https://api.elsevier.com/content/article/PII:S0923753424017083?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753424017083?httpAccept=text/plain

Abstract P1-15-01: Withdrawn

Συγγραφείς: Metzger Filho, O, primary, Janiszewska, M, additional, Guo, H, additional, Yardley, D, additional, Mayer, I, additional, Spring, L, additional, Arteaga, C, additional, Wrabel, E, additional, DeMeo, M, additional, Freedman, R, additional, Tolaney, S, additional, Waks, A, additional, Bardia, A, additional, Parsons, H, additional, Partridge, A, additional, Mayer, E, additional, King, T, additional, Polyak, K, additional, Viale, G, additional, Winer, E, additional, Krop, I, additional

Πηγή: Cancer Research. 2019/02/15

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Συγγραφείς: Filho O. M., Viale G., Stein S., Trippa L., Yardley D. A., Mayer I. A., Abramson V. G., Arteaga C. L., Spring L. M., Waks A. G., Wrabel E., DeMeo M. K., Bardia A., Dell'Orto P., Russo L., King T. A., Polyak K., Michor F., Winer E. P., Krop I. E.

Συνεισφορές: O.M. Filho, G. Viale, S. Stein, L. Trippa, D.A. Yardley, I.A. Mayer, V.G. Abramson, C.L. Arteaga, L.M. Spring, A.G. Wak, E. Wrabel, M.K. DeMeo, A. Bardia, P. Dell'Orto, L. Russo, T.A. King, K. Polyak, F. Michor, E.P. Winer, I.E. Krop

Θεματικοί όροι: Settore MED/08 - Anatomia Patologica

Relation: info:eu-repo/semantics/altIdentifier/pmid/33941592; info:eu-repo/semantics/altIdentifier/wos/WOS:000704194700026; volume:11; issue:10; firstpage:2474; lastpage:2487; numberofpages:14; journal:CANCER DISCOVERY; https://hdl.handle.net/2434/883024

Διαθεσιμότητα: https://hdl.handle.net/2434/883024
https://doi.org/10.1158/2159-8290.CD-20-1557

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

Συγγραφείς: Waks AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Segui E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Li T; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Lipsyc-Sharf M; UCLA David Geffen School of Medicine, Los Angeles, California., Kallfelz E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., DiLullo M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Patel A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Rahman T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Junkins K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Rahee H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Frey AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kelly E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Stalteri M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wrabel E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Williams A; Biovica International, Uppsala, Sweden., Parsons HA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Poorvu PD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Partridge AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Abravanel DL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Poorvu N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., LeStage B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Sicinski P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Tayob N; Harvard Medical School, Boston, Massachusetts.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.

Πηγή: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Oct 01; Vol. 32 (19), pp. 4250-4260.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase I

Στοιχεία περιοδικού: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Breast Neoplasms*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Aminopyridines/administration & dosage ; Aminopyridines/adverse effects ; Fulvestrant/administration & dosage ; Erb-b2 Receptor Tyrosine Kinases/metabolism ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Receptors, Progesterone/metabolism ; Receptors, Estrogen/metabolism ; Protein Kinase Inhibitors/administration & dosage ; Humans ; Female ; Middle Aged ; Aged ; Adult ; Maximum Tolerated Dose

Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer.

Συγγραφείς: Tesch ME; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Graham N; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Snow C; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Stever CE; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Parker TS; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Luo M; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Martino IG; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Drummey B; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Virani S; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Santos K; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Bsat J; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Ryan S; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Beth Israel Deaconess Medical Center, Boston, MA, USA., Hughes ME; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Yale Cancer Center, New Haven, CT, USA., Wrabel E; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Tung N; Beth Israel Deaconess Medical Center, Boston, MA, USA., Lo S; Stamford Health, Stamford, CT, USA., Ahmad N; Berkshire Medical Center, Pittsfield, MA, USA., Faggen M; Dana-Farber Cancer Institute South Shore, Weymouth, MA, USA., Sinclair N; Dana-Farber Cancer Institute Milford and Foxborough, Milford, MA, USA., Constantinou M; Lifespan Comprehensive Cancer Center, Providence, RI, USA., Sinclair S; Northern Light Eastern Maine Medical Center, Bangor, ME, USA., Meisel JL; Winship Cancer Institute of Emory University, Atlanta, GA, USA., King TA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA.; Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA., Mittendorf EA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA., Tayob N; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Lin NU; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Partridge AH; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Winer EP; Yale Cancer Center, New Haven, CT, USA., Tolaney SM; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Garrido-Castro AC; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Ana_Garrido-Castro@DFCI.HARVARD.EDU.; Harvard Medical School, Boston, MA, USA. Ana_Garrido-Castro@DFCI.HARVARD.EDU.

Πηγή: Breast cancer research and treatment [Breast Cancer Res Treat] 2026 Jul 30; Vol. 218 (2). Date of Electronic Publication: 2026 Jul 30.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Triple Negative Breast Neoplasms*/therapy , Triple Negative Breast Neoplasms*/epidemiology , Triple Negative Breast Neoplasms*/psychology , Triple Negative Breast Neoplasms*/pathology , Health Knowledge, Attitudes, Practice* , Patient Participation* , Clinical Trials as Topic*, Humans ; Female ; Middle Aged ; Aged ; Self Report ; Neoplasm Staging ; Adult ; Prospective Studies

Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.

Συγγραφείς: Weiss A; Division of Surgical Oncology, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA. Anna_weiss@urmc.rochester.edu.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. Anna_weiss@urmc.rochester.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Anna_weiss@urmc.rochester.edu.; Harvard Medical School, Boston, MA, USA. Anna_weiss@urmc.rochester.edu., Jin Q; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Tayob N; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Wrabel E; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Carter J; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Constantine M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Faggen M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Block C; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fenton MA; Division of Oncology, Lifespan Cancer Institute, Providence, RI, USA., Lo KMS; Division of Medical Oncology, Stamford Health, Stamford, CT, USA., Openshaw T; Eastern Maine Medical Center, Bangor, ME, USA., Yardley D; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Kennedy L; Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Bedrosian I; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mittendorf EA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Jeselsohn R; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Metzger Filho O; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., King TA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Πηγή: Annals of surgical oncology [Ann Surg Oncol] 2026 Mar; Vol. 33 (3), pp. 2275-2283. Date of Electronic Publication: 2025 Nov 23.

Τύπος έκδοσης: Journal Article; Randomized Controlled Trial

Στοιχεία περιοδικού: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Neoadjuvant Therapy*/mortality , Breast Neoplasms*/pathology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/surgery , Carcinoma, Lobular*/pathology , Carcinoma, Lobular*/drug therapy , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Lymph Node Excision*/mortality , Neoplasm Recurrence, Local*/pathology, Pyridines/administration & dosage ; Piperazines/administration & dosage ; Piperazines/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Receptors, Estrogen/metabolism ; Humans ; Female ; Middle Aged ; Aged ; Axilla ; Survival Rate ; Follow-Up Studies ; Prognosis ; Sentinel Lymph Node Biopsy

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.

Συγγραφείς: Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu., Cha J; Harvard Medical School, Boston, MA, USA., Binboga Kurt B; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Chu X; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Jovanović B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Loxo@Lilly, Indianapolis, IN, USA., Zhou A; Harvard Medical School, Boston, MA, USA., Hughes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Russo D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., DiLullo M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wrabel E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jeselsohn R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Carter J; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Chen YS; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Li T; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Tayob N; Harvard Medical School, Boston, MA, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Schnitt SJ; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Goel S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.

Πηγή: NPJ breast cancer [NPJ Breast Cancer] 2026 Feb 13; Vol. 12 (1). Date of Electronic Publication: 2026 Feb 13.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer.

Συγγραφείς: Fu J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Pimenta E; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Titchen B; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Harvard Division of Medical Sciences PhD Program in Biological and Biomedical Sciences, Harvard University, Cambridge, MA, USA., Bi K; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Camp S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pappa T; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Keenan T; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Shannon E; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Vigneau S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bemus M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nag A; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Thorner AR; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Park J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., DiLullo M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Wrabel E; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Jeselsohn R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA., Abravanel DL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Van Allen EM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. eliezerm_vanallen@dfci.harvard.edu.; Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu.

Πηγή: Nature communications [Nat Commun] 2025 Nov 28; Vol. 16 (1), pp. 10704. Date of Electronic Publication: 2025 Nov 28.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Breast Neoplasms*/immunology , Cellular Reprogramming*/drug effects , Cellular Reprogramming*/genetics , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology ; Paclitaxel/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Receptors, Estrogen/metabolism ; Macrophages/immunology ; Macrophages/drug effects ; Receptors, Progesterone/metabolism ; Gene Expression Regulation, Neoplastic/drug effects ; T-Lymphocytes/immunology ; Humans ; Female ; Neoadjuvant Therapy ; Middle Aged ; Albumins

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.

Συγγραφείς: Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Fu J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Chu X; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Binboga Kurt B; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Li T; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kuntz TM; Harvard Chan Microbiome Analysis Core, Harvard TH Chan School of Public Health, Boston, MA, USA., Shen Y; Harvard Medical School, Boston, MA, USA.; Yale School of Medicine, New Haven, CT, USA., Yang D; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Radiation Oncology, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Meli K; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Reardon B; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Park J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Partridge A; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Abravanel D; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Jeselsohn R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Wrabel E; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Alberti J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., DiLullo M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Chen S; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Mohammed-Abreu A; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Sun X; Vanderbilt University Medical Center, Nashville, TN, USA., Balko JM; Vanderbilt University Medical Center, Nashville, TN, USA., Kleijn M; Agendia, Inc., Irvine, CA, USA., Audeh W; Agendia, Inc., Irvine, CA, USA., Morgan XC; Harvard Chan Microbiome Analysis Core, Harvard TH Chan School of Public Health, Boston, MA, USA., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Yale Cancer Institute, New Haven, CT, USA., Tayob N; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Van Allen EM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. sara_tolaney@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. sara_tolaney@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. sara_tolaney@dfci.harvard.edu.

Πηγή: Nature communications [Nat Commun] 2025 Nov 28; Vol. 16 (1), pp. 10705. Date of Electronic Publication: 2025 Nov 28.

Τύπος έκδοσης: Journal Article; Randomized Controlled Trial

Στοιχεία περιοδικού: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Paclitaxel*/administration & dosage , Paclitaxel*/therapeutic use , Paclitaxel*/adverse effects , Breast Neoplasms*/drug therapy , Breast Neoplasms*/metabolism , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Albumins*/administration & dosage , Albumins*/therapeutic use , Albumins*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Neoadjuvant Therapy/methods ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/genetics ; Biomarkers, Tumor/metabolism ; Biomarkers, Tumor/genetics ; Erb-b2 Receptor Tyrosine Kinases/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Humans ; Female ; Pilot Projects ; Middle Aged ; Adult ; Aged ; Treatment Outcome

A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer.

Συγγραφείς: Goel S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Jovanović B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Chu X; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Hughes M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Erick TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Russo D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., DiLullo M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wrabel E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Jeselsohn R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Tayob N; Harvard Medical School, Boston, Massachusetts.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Mittendorf E; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Schnitt S; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.

Πηγή: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Apr 14; Vol. 31 (8), pp. 1427-1436.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase II

Στοιχεία περιοδικού: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Benzimidazoles*/administration & dosage , Benzimidazoles*/adverse effects , Benzimidazoles*/therapeutic use , Aminopyridines*/administration & dosage , Aminopyridines*/adverse effects , Aminopyridines*/therapeutic use , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/mortality , Triple Negative Breast Neoplasms*/genetics , Retinoblastoma Protein*/genetics , Retinoblastoma Protein*/metabolism, Humans ; Female ; Middle Aged ; Adult ; Aged ; Neoplasm Metastasis ; Treatment Outcome ; Biomarkers, Tumor

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer.

Συγγραφείς: Garrido-Castro AC; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Graham N; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ali LR; Harvard Medical School, Boston, Massachusetts, USA.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Herold C; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Takeda Oncology, Cambridge, Massachusetts, USA., Desrosiers J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Do K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Parsons H; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Li T; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Goel S; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., DiLullo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA., Wrabel E; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA., Williams AJ; Biovica International AB, Uppsala, Uppsala County, Sweden., Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA., Dougan SK; Harvard Medical School, Boston, Massachusetts, USA.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Tayob N; Harvard Medical School, Boston, Massachusetts, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Tolaney SM; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts, USA sara_tolaney@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.

Πηγή: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Feb 25; Vol. 13 (2). Date of Electronic Publication: 2025 Feb 25.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase I

Στοιχεία περιοδικού: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Purines*/pharmacology , Purines*/therapeutic use , Purines*/administration & dosage , Aminopyridines*/pharmacology , Aminopyridines*/therapeutic use , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Fulvestrant*/pharmacology , Fulvestrant*/therapeutic use , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/pharmacology, Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Humans ; Female ; Middle Aged ; Aged ; Adult ; Neoplasm Metastasis ; Maximum Tolerated Dose

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.

Συγγραφείς: Gómez Tejeda Zañudo J; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Barroso-Sousa R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil., Jain E; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Repare Therapeutics, Cambridge, MA, USA., Jin Q; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, MA, USA., Li T; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, MA, USA., Buendia-Buendia JE; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cellarity, Somerville, MA, USA., Pereslete A; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Abravanel DL; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Ferreira AR; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal., Wrabel E; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Helvie K; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Overmoyer B; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Tayob N; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Wagle N; Cancer Program, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, USA. Nikhil_Wagle@dfci.harvard.edu.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Nikhil_Wagle@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. Nikhil_Wagle@dfci.harvard.edu.; Genentech, South San Francisco, CA, USA. Nikhil_Wagle@dfci.harvard.edu.

Πηγή: Nature communications [Nat Commun] 2024 Mar 19; Vol. 15 (1), pp. 2446. Date of Electronic Publication: 2024 Mar 19.

Τύπος έκδοσης: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Στοιχεία περιοδικού: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/metabolism , Androstadienes* , Piperazines* , Pyridines*, Everolimus/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Erb-b2 Receptor Tyrosine Kinases/metabolism ; Cyclin-Dependent Kinase 4/metabolism ; Humans ; Female ; Transcriptome ; Gene Expression Profiling ; Genomics

Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial.

Συγγραφείς: Weiss A; From the Division of Surgical Oncology, Department of Surgery, University of Rochester, Rochester, NY (Weiss)., Jin Q; Department of Data Science (Jin, Tayob), Dana-Farber Cancer Institute Boston, MA., Waks AG; Division of Medical Oncology (Waks, Metzger-Filho), Dana-Farber Cancer Institute Boston, MA.; Harvard Medical School, Boston, MA (Waks, Tayob, King, Metzger-Filho).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA (Waks, Wrabel, King, Metzger-Filho)., Yardley D; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN (Yardley)., Spring LM; Massachusetts General Hospital, Boston, MA (Spring)., Wrabel E; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA (Waks, Wrabel, King, Metzger-Filho)., Tayob N; Department of Data Science (Jin, Tayob), Dana-Farber Cancer Institute Boston, MA.; Harvard Medical School, Boston, MA (Waks, Tayob, King, Metzger-Filho)., Viale G; Division of Pathology, European Institute of Oncology, IRCCS and University of Milan, Milan, Italy (Viale)., Krop IE; Yale Cancer Center, New Haven, CT (Krop)., King TA; Harvard Medical School, Boston, MA (Waks, Tayob, King, Metzger-Filho).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA (Waks, Wrabel, King, Metzger-Filho).; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA (King)., Metzger-Filho O; Division of Medical Oncology (Waks, Metzger-Filho), Dana-Farber Cancer Institute Boston, MA.; Harvard Medical School, Boston, MA (Waks, Tayob, King, Metzger-Filho).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA (Waks, Wrabel, King, Metzger-Filho).

Πηγή: Journal of the American College of Surgeons [J Am Coll Surg] 2024 Mar 01; Vol. 238 (3), pp. 303-311. Date of Electronic Publication: 2023 Dec 04.

Τύπος έκδοσης: Clinical Trial, Phase II; Journal Article

Στοιχεία περιοδικού: Publisher: Lippincott Williams & Wilkins, Inc Country of Publication: United States NLM ID: 9431305 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1190 (Electronic) Linking ISSN: 10727515 NLM ISO Abbreviation: J Am Coll Surg Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/surgery , Breast Neoplasms*/pathology , Neoadjuvant Therapy* , Antibodies, Monoclonal, Humanized*, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Erb-b2 Receptor Tyrosine Kinases/therapeutic use ; Ado-Trastuzumab Emtansine/therapeutic use ; Humans ; Female ; Prospective Studies

Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.

Συγγραφείς: Weiss A; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Li T; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Department of Data Science (Li, Tayob)., Desai NV; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston MA (Desai, Tung)., Tung NM; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston MA (Desai, Tung)., Poorvu PD; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Partridge AH; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Nakhlis F; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Dominici L; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Sinclair N; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Spring LM; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Hematology-Oncology, Massachusetts General Hospital, Boston MA (Spring)., Faggen M; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Constantine M; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Krop IE; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks)., Wrabel E; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks)., Alberti J; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks)., Chikarmane S; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Radiology (Chikarmane), Brigham and Women's Hospital, Boston MA., Tayob N; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Department of Data Science (Li, Tayob)., King TA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Tolaney SM; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Winer EP; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Mittendorf EA; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Waks AG; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA.

Πηγή: Journal of the American College of Surgeons [J Am Coll Surg] 2023 Aug 01; Vol. 237 (2), pp. 247-256. Date of Electronic Publication: 2023 May 17.

Τύπος έκδοσης: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

Στοιχεία περιοδικού: Publisher: Lippincott Williams & Wilkins, Inc Country of Publication: United States NLM ID: 9431305 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1190 (Electronic) Linking ISSN: 10727515 NLM ISO Abbreviation: J Am Coll Surg Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Paclitaxel/therapeutic use ; Erb-b2 Receptor Tyrosine Kinases/therapeutic use ; Trastuzumab/therapeutic use ; Female ; Humans ; Neoadjuvant Therapy ; Prospective Studies ; Antibodies, Monoclonal, Humanized

Pathogen-inspired drug delivery to the central nervous system.

Συγγραφείς: McCall RL; Barrow Brain Tumor Research Center; Barrow Neurological Institute ; Phoenix, AZ USA., Cacaccio J; Blue Ocean Biomanufacturing , Worcester, MA USA., Wrabel E; Nemucore Medical Innovations, Inc. ; Worcester, MA USA., Schwartz ME; Nemucore Medical Innovations, Inc. ; Worcester, MA USA., Coleman TP; Blue Ocean Biomanufacturing , Worcester, MA USA ; Nemucore Medical Innovations, Inc. ; Worcester, MA USA ; Center for Translational Cancer Nanomedicine; Northeastern University ; Boston, MA USA ; Foundation for the Advancement of Personalized Medicine Manufacturing ; Phoenix, AZ USA., Sirianni RW; Barrow Brain Tumor Research Center; Barrow Neurological Institute ; Phoenix, AZ USA.

Πηγή: Tissue barriers [Tissue Barriers] 2014 Aug 08; Vol. 2 (4), pp. e944449. Date of Electronic Publication: 2014 Aug 08 (Print Publication: 2014).

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101601065 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8362 (Print) Linking ISSN: 21688362 NLM ISO Abbreviation: Tissue Barriers Subsets: PubMed not MEDLINE